You are here:
Home / Investors / Events & Presentations

Tools

Events & Presentations

Upcoming Events

Archived Investor Events and Presentations

Archived Scientific Presentations

Date Documents
December 6, 2020
Complete Responses in Relapsed/ Refractory AML Patients on a Weekly Dosing Schedule of Vibecotamab, a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Results of a Phase 1 Study
November 9, 2020
Preliminary Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of XmAb®20717, a PD-1 x CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
November 9, 2020
Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
November 9, 2020
PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors
November 9, 2020
Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
October 2, 2020
NANETS 2020: Preliminary Safety, PK/PD, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Patients With Advanced Neuroendocrine Tumors
June 22, 2020
AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies
June 22, 2020
AACR 2020: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models
June 22, 2020
AACR 2020: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity
June 22, 2020
AACR 2020: Affinity tuned XmAb® 2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells
December 9, 2019
ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL
March 4, 2019
Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format
December 3, 2018
ASH 2018: Complete Responses in r/r AML Patients on a Weekly Dosing Schedule of XmAb®14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
December 3, 2018
ASH 2018: Regulatory T cell selective IL-2-Fc fusion proteins for the treatment of autoimmune diseases
November 9, 2018
SITC 2018: An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure
November 9, 2018
SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation
October 21, 2018
ACR 2018: Top-line Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
April 18, 2018
AACR 2018: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure
April 16, 2018
AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation
November 13, 2017
SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T CellActivation and Proliferation
November 13, 2017
SITC 2017: Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation
November 8, 2017
ACR 2017: Final Results from Phase 2 Study of XmAb 5871 in IgG4-Related Disease
June 16, 2017
EULAR 2017: Interim Results of a Phase 2 Study of XmAb®5871, a Reversible B Cell Inhibitor, in IgG4-Related Disease
April 4, 2017
AACR 2017: IL 15/IL 15Ra; heterodimeric Fc-fusions with extended half-lives
April 4, 2017
AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation
April 4, 2017
AACR 2017: Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors
November 13, 2016
Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease
November 9, 2016
2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation
November 9, 2016
2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation
June 12, 2015
European League Against Rheumatism (EULAR) 2015 Annual Meeting Poster: A Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis
December 7, 2014
American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111
December 7, 2014
Xencor American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD123 x Anti-CD3 Bispecific Antibodies in Acute Myleogenous Leukemia Chu, et al, Abstract ID# 2316